Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446480 | 1.00 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1CHRM2CHRM1 | |
| SCHEMBL1891129 | 1.00 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1CHRM2CHRM1 | |
| SCHEMBL28150230 | 0.95 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1CHRM2CHRM1 | |
| SCHEMBL22653971 | 0.89 | CHRM2 (0.47) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL27443090 | 0.89 | CHRM2 (0.47) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL559852 | 0.80 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1CHRM2CHRM1 | |
| SCHEMBL1010839 | 0.80 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1CHRM2CHRM1 | |
| SCHEMBL1550543 | 0.80 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1CHRM2CHRM1 | |
| SCHEMBL1115598 | 0.80 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1CHRM2CHRM1 | |
| SCHEMBL357043 | 0.80 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101535299-B | 5-lipoxygenase-activating protein (flap) inhibitors | PANMIRA PHARMACEUTICALS LLC | 2013-09-25 | — | — | CN | disclosed |
| US-8173659-B2 | Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-05-08 | — | — | US | disclosed |
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-22 | — | — | US | disclosed |
| US-7947686-B2 | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-24 | — | — | US | disclosed |
| CN-101535299-A | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-1689720-B1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2009-04-15 | — | — | EP | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K3, MAP3K1, MAP3K19 | HSD17B10 4006/4885SMN1; SMN2 3711/4885NPC1 3499/4885 |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K19 | HSD17B10 4006/4885SMN1; SMN2 3711/4885NPC1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.